Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1998

View Archived Issues

New azapeptide HIV protease inhibitor profiled at ICAAC

Guilford achieves development milestone in Amgen collaboration

A novel use described for the proton pump inhibitor pantoprazole

Celgene initiates development of Thalomid for hematological cancers

Neurotrophic/neuroprotective compounds claimed by Sanofi

New arthritis Rx now available in Japan

Sanofi describes new series acting on vasopressin and/or oxytocin receptors

Peptide analgesics described by Asahi Glass

Antisecretory benzodiazepines for GI disorders designed at Zeria

PowderJect system effectively delivers local anesthetic without a needle

Dual LTD4 antagonists/histamine release inhibitors in development at Daiichi

Chrysalis begins clinical evaluation of wound-healing agent

Nyotran effective against treatment-resistant fungal infections in phase II study

Pyrrole antiviral agents prepared and evaluated at Rhone-Poulenc Rorer

Yamanouchi and Merck KGaA work together to develop Na+/H+ exchange inhibitors

Yoshitomi optimizes quinolones for anti-H. pylori activity: selects Y-34867 as development candidate

SYN-2869: new triazole antifungal agent selected for further development

New study shows that LYMErix can be given according to a flexible dosing schedule

Novel assay method detects fungal infections earlier and more accurately

Carbapenems in development at Korean research institute characterized at ICAAC

SB initiates phase III trials with fluoroquinolone antibiotic

Valaciclovir therapy suppresses viral shedding in patients with genital herpes

Potent, broad-spectrum, orally active 2-pyridone antibacterial enters Abbott pipeline

Guilford prototype PARP inhibitor proves effective in animal models of stroke, heart attack

Merck & Co. designs orally active beta3-adrenoceptor partial agonists

Chirocaine shows increased safety in obstetric population

IB-367: preclinical results presented at ICAAC support clinical trials in oral mucositis

AxyS Pharmaceuticals discontinues development of APC-366 for asthma